LianBio
NASDAQ:LIAN
LianBio
Cash Equivalents
LianBio
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LianBio
NASDAQ:LIAN
|
Cash Equivalents
$79.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is LianBio's Cash Equivalents?
Cash Equivalents
79.2m
USD
Based on the financial report for Dec 31, 2022, LianBio's Cash Equivalents amounts to 79.2m USD.
What is LianBio's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
22%
Over the last year, the Cash Equivalents growth was -65%. The average annual Cash Equivalents growth rates for LianBio have been 22% over the past three years .